Exai Bio Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Exai Bio is a biotechnology company headquartered in Palo Alto, California, focused on next-generation liquid biopsy technologies. The company develops an RNA-based liquid biopsy platform that uses artificial intelligence to deliver clinical insights for early cancer detection and accurate diagnosis. Exai Bio traces its origins to technology from the UCSF laboratory of Dr. Hani Goodarzi and brings together leaders from academia and industry in RNA biology, liquid biopsy, and AI/ML. The company employs 11-50 people and has publicly reported data from studies, including a 3,300-subject study demonstrating detection of multiple cancer types at the earliest stages from a single blood sample, as well as data on early breast cancer detection announced in 2023. In 2024, Exai Bio appointed Dave Daly as Chief Executive Officer and later added Karen E. Knudsen to its Board of Directors, and the company is backed by investors including Section 32, Casdin Capital, and Two Sigma Ventures.